Currently, the FDA has approved five anti-PD-1 or anti-PD-L1 antibodies (pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab) for the treatment of 11 types of cancer, including refractory melanoma, advanced non-small cell lung cancer, Merkel cell carcinoma, Hodgkin’s lymphoma, highly microsatellite instability (MSI-h) tumors, head and neck cancer, bladder cancer, urothelial carcinoma, gastric esophageal cancer, hepatocellular carcinoma, and renal cell carcinoma (69). This evidence concerns the gene CD274 and hereditary clear cell renal cell carcinoma.